Lars Asphaug
- Health Economist; PhD
- +47 99 50 00 63
Publications 2024
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
BJU Int, 133 (6), 680-689
DOI 10.1111/bju.16314, PubMed 38469686
Publications 2023
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
BMJ Open, 13 (3), e070071
DOI 10.1136/bmjopen-2022-070071, PubMed 36940951
Publications 2022
Cost-effectiveness analysis of a psychosocial web-based intervention for adolescents distressed by a visible difference: Results from a randomized controlled trial in Norway
Scand J Psychol, 64 (3), 268-277
DOI 10.1111/sjop.12885, PubMed 36367227
Publications 2020
Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis
Hepatology, 71 (6), 2093-2104
DOI 10.1002/hep.30979, PubMed 31595545
Publications 2019
The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway
MDM Policy Pract, 4 (1), 2381468318821103
DOI 10.1177/2381468318821103, PubMed 30746499